HOUSTON, Jan. 13, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biotechnology company specializing in the
development of novel treatments for brain tumors, today announced
it has entered into a licensing agreement with MD Anderson to
investigate WP1244, an entirely new class of DNA-binding agents
designed to cross the blood brain barrier for the potential the
treatment of primary and metastatic brain cancers.
This agreement marks the Company's first direct relationship
with MD Anderson, the largest cancer research and treatment
institute in the world, and allows for the continued development of
WP1244, a new class of DNA-binding agents shown to have high
anti-tumor activity. WP1244 was designed using a "modular"
strategy, which combines intercalation and groove-binding modes
into molecules with the requisite chirality and binding-site size
to impart meaningful selectivity. Previous pre-clinical tests have
demonstrated the agent's ability to cross the blood barrier in
animal models with no acute clinically observable toxicity. The
Company is currently collaborating with MD Anderson on terms to
conduct a sponsored research agreement of this novel class of
agent.
"Our licensing agreement with MD Anderson has allowed CNS to
double its portfolio with the addition of WP1244. We are extremely
excited to continue the investigation of this entirely new class of
DNA-binding agent in our first direct relationship with MD
Anderson," stated CEO of CNS, John M.
Climaco. "We believe the compound demonstrates enormous
potential through its novel mechanism of action, ability to cross
the blood-brain barrier, and tremendous potency, 500 times that of
classic DNA binding agents such as daunorubicin. WP1244 has shown
to be mechanistically and biologically novel and selective, and its
addition to our pipeline furthers our goal of being the leading
developer of organ-targeted cancer therapeutics. We look forward to
both furthering the clinical development of WP1244 and deepening
our relationship with MD Anderson through a sponsored research
agreement."
About WP1244
WP1244 is a novel DNA binding agent with
relatively high molecular weight (981.3 MW) having a polyamide
moiety attached to the amino sugar. WP1244 is exceedingly potent
having in vitro IC50 values in the subnanomolar range and is
currently being studied for its therapeutic potential in
preclinical studies. A previous 5-mice pilot study performed with
WP1244 confirmed the presence of WP1244 in murine brain tissue.
WP1244 was designed utilizing a "modular" design strategy, which
combines intercalation and groove-binding modes into molecules with
the requisite chirality and binding-site size to impart meaningful
selectivity. Pre-clinical studies of WP1244 have demonstrated its
potential ability to cross the blood-brain barrier in animal
models. WP1244 was developed at the MD Anderson Cancer Center in
the Department of Experimental Therapeutics as a collaborative
effort with the Neuro-Oncology Department and Pharmaceutical
Development Center.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is
a biotechnology company specializing in the development of novel
treatments for primary and metastatic brain and central nervous
system tumors. Its lead candidate Berubicin is proposed for
the treatment of glioblastoma, a type of brain cancer currently
considered incurable, as well as for pancreatic and ovarian
cancers, and lymphomas. The Company entered into an
intellectual property (IP) agreement with Houston Pharmaceuticals,
Inc. and a Purchase Agreement with Reata. For more
information, visit www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to further
the clinical development of WP1244. These statements relate to
future events, future expectations, plans and prospects. Although
CNS believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
CNS has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Risk
Factors" in the Form S-1 we filed with the SEC on October 7, 2019. Any forward-looking statements
contained in this release speak only as of its date. CNS undertakes
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-licenses-breakthrough-technology-from-md-anderson-doubling-its-drug-pipeline-300985388.html
SOURCE CNS Pharmaceuticals, Inc.